Tetrapeptide Compositions for Retinal Cell Death and ROS Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for degenerative and age-related disorders, particularly eye-related conditions such as age-related macular degeneration, are inadequate and do not effectively address the underlying cell death cycle, leading to irreversible vision loss and blindness.
Innovation Solution
Pharmaceutical compositions containing peptides denoted ZEP3 and ZEP4, or their salts, which attenuate reactive oxygen species (ROS) formation and increase cell viability under stress conditions, are administered to treat, prevent, or reverse degenerative and trauma-induced disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies (e.g., hypotensive agents, carbonic anhydrase inhibitors) are administered to reduce intra-ocular pressure or aqueous production, then intra-ocular pressure is reduced, but the underlying cell death cycle in degenerative disorders is not interfered with, leading to inadequate treatment of age-related deterioration
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of cell death in degenerative disorders by using peptides that selectively interfere with the cell death cycle, separating this therapeutic action from conventional intra-ocular pressure reduction mechanisms. The peptides pGlu-Asn-Trp-Lys(Octanoyl)-OH and pGlu-Asn-Trp-Thr-OH specifically address cellular deterioration without being limited to pressure-related pathways.
Solution Approach 2:
The invention changes the therapeutic parameter from mechanical/physiological pressure control to molecular/cellular level intervention. By administering peptides that modulate cell death pathways at the molecular level, the treatment addresses the fundamental biological parameter of cellular viability rather than just the physiological parameter of intra-ocular pressure.
2Speed
If therapies are designed to slow down disease progression, then progression rate is reduced, but the diseases are typically considered irreversible and significant adverse effects occur with limited efficacy
Solution Approach 1:
The patent applies preliminary action by administering peptides that proactively protect cells from death cycle progression before irreversible damage occurs. The peptides pGlu-Asn-Trp-Lys(Octanoyl)-OH and pGlu-Asn-Trp-Thr-OH are designed to intervene early in the pathological process, preventing cell death rather than merely slowing its progression, thereby potentially reversing early-stage degenerative changes.
3Stress or pressure
If conventional drugs are administered to treat glaucoma by increasing aqueous flow or decreasing aqueous production, then intra-ocular pressure is reduced, but old-age deterioration of retinal function is not treated since the cell death cycle itself is not interfered with
Solution Approach 1:
The patent introduces peptides as intermediary substances that mediate between the physiological state and the pathological cell death process. The peptides pGlu-Asn-Trp-Lys(Octanoyl)-OH and pGlu-Asn-Trp-Thr-OH act as molecular mediators that specifically target and modulate the cell death cycle, providing a bridge between pressure management and cellular protection that conventional drugs fail to establish.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides reduce ROS formation, thereby mitigating cellular damage and improving cell viability, providing therapeutic benefits in treating and preventing degenerative and trauma-induced disorders, including eye diseases, even in the absence of pain or inflammation.
Implementation Method 1
The pathology of these diseases is typically attributed to the aberrant accumulation of protein aggregates resulting in from various pathogenic mechanisms including oxidative stress induced by Reactive Oxygen Species (ROS)
Implementation Method 2
peptides denoted ZEP3 and ZEP4 and salts thereof attenuate the formation of reactive oxygen species (ROS) and increase viability of human primary corneal epithelial cells under stress conditions
Data Source
AI summary
Pharmaceutical compositions comprising specific tetrapeptides, for use in treating, preventing, minimizing, diminishing or reversing degenerative, age-related and trauma-induced disorders, particularly of the eye, are provided.